$ORTX News

Last published 2y ago

2y agoORTXOrchard Therapeutics Announces Multiple Presentations at ASGCT 2024GlobeNewswireTOKYO, LONDON and BOSTON, May 07, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe, today
2y agoORTXOrchard Therapeutics Co-founder and Chief Executive Officer Dr. Bobby Gaspar Named to Inaugural 2024 TIME100 Health ListGlobeNewswireTOKYO, LONDON and BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe, today
2y agoORTXOrchard Therapeutics Outlines U.S. Launch Plans for Lenmeldy™ (atidarsagene autotemcel), the Only Approved Therapy for Children with Early-onset Metachromatic LeukodystrophyGlobeNewswireFive specialized treatment centers being qualified across the U.S. to minimize travel burden on eligible patients and their families Orchard Assist patient services program to provide individualized support throughout
2y agoORTXOrchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene autotemcel), the Only Therapy for Eligible Children with Early-onset Metachromatic Leukodystrophy in the U.S.GlobeNewswireTOKYO and LONDON and BOSTON, March 18, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe,
2y agoCGON ORTX TLSIORI Capital Raises $260 Million for Second Life Sciences FundBusiness Wire- Fundraise closed above its original target, reflecting strong interest from institutional, strategic and high net worth investors globally ORI Capital today announced the final close of its second fund, ORI Fund II
2y agoORTXOrchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler SyndromeGlobeNewswireGene therapy being developed as a one-time treatment to address the underlying cause of the disease by inserting a functional copy of the human IDUA gene into a patient's own hematopoietic stem cells HURCULES study to
2y agoORTXOrchard Therapeutics Announces Multiple Presentations at the 20th Annual WORLDSymposiumGlobeNewswireBOSTON and LONDON, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, a global gene therapy leader recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients
2y agoORTXOrchard Therapeutics Announces Agreement with the Beneluxa Consortium Enabling Reimbursed Access to LibmeldyGlobeNewswireBOSTON and LONDON, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, a global gene therapy leader, today announced the company has reached an agreement with the Beneluxa Initiative on Pharmaceutical Policy
2y agoORTXKyowa Kirin successfully completes acquisition of Orchard Therapeutics, a global gene therapy leader for rare diseasesGlobeNewswireTOKYO and LONDON and BOSTON, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) a Japan-based global specialty pharmaceutical company (J-GSP) discovering and developing novel medicines
2y agoKYMR NBTX ORTX SLN+1INVO Bioscience Files S-4 Registration and Preliminary Joint Proxy Statements in Connection with Merger with NAYA Biosciences, NAYA Announces New Board DirectorsGlobeNewswireINVO (NASDAQ: INVO) and NAYA Biosciences expect to close their previously announced merger in the first quarter of 2024Experienced, entrepreneurial leadership team to help structure merged public company and accelerate
2y agoORTXOrchard Therapeutics Receives Swissmedic Approval for Libmeldy in Early-onset MLDGlobeNewswireBOSTON and LONDON, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a global gene therapy leader, today announced the Swiss Agency for Therapeutic Products (Swissmedic) has approved Libmeldy®
2y agoORTXOrchard Therapeutics Receives U.S. FDA Fast Track Designation for OTL-203 in MPS-IHGlobeNewswirePreviously reported results from ongoing proof-of-concept study showed extensive metabolic correction, continued cognitive, motor, and physical development, as well as early improvements in skeletal health
2y agoORTXOrchard Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Business AccomplishmentsGlobeNewswireReported $5.6 million in quarterly Libmeldy net revenue and $12.7 million year-to-date Planned acquisition by Kyowa Kirin valued at up to $477.6 million with an anticipated closing in the first quarter of 2024
3y agoPNT VERY MRTX ORTXMoore Kuehn Encourages PNT, VERY, MRTX, and ORTX Investors to Contact Law FirmPR NewswireMoore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims...
3y agoORTXOrchard Therapeutics Announces Presentation of Additional Positive Data from Proof-of-concept Study of OTL-203 in MPS-IH at ESGCT 2023GlobeNewswireBOSTON and LONDON, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a global gene therapy leader, today announced a range of interim clinical outcomes, in addition to the previously reported
3y agoORTXOrchard Therapeutics Announces Multiple Presentations at ESGCT 2023GlobeNewswireEight presentations highlight the differentiated profile and broad applicability of the company's HSC gene therapy platform Data from proof-of-concept study of OTL-203 in MPS-IH demonstrate favorable outcomes for
3y agoMRTX ORTX SP SRTMoore Kuehn Encourages SP, ORTX, MRTX, and SRT Investors to Contact Law FirmGlobeNewswireNEW YORK, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the
3y agoORTXKyowa Kirin to Acquire Orchard TherapeuticsGlobeNewswire-Orchard Therapeutics is a global gene therapy leader with experience successfully developing and commercializing medicines for rare diseases--Acquisition enriches Kyowa Kirin's portfolio, enables the development of
3y agoORTXOrchard Therapeutics Announces Acceptance of Biologics License Application for OTL-200 in MLD and Receives Priority ReviewGlobeNewswirePDUFA date set for March 18, 2024 OTL-200 would be the first and only treatment in the U.S. for early-onset MLD Previously published data demonstrated administration of one-time gene therapy enables sustained
3y agoORTXOrchard Therapeutics Announces Presentation of Data Comprising the Clinical Package for the OTL-200 BLA in MLD at the SSIEM Annual Symposium 2023GlobeNewswireAdministration of one-time gene therapy resulted in statistically significant improvement in severe motor impairment-free survival with up to 12 years of follow-up (median 6.76 years) Composite primary endpoint used
3y agoORTXOrchard Therapeutics plc (ORTX) Q2 2023 Earnings Call TranscriptEarnings Call Transcripts
3y agoORTXOrchard Therapeutics Strongly Supports Enactment of Newborn Metabolic Screening Act in Illinois, Adding Metachromatic Leukodystrophy to Statewide PanelGlobeNewswireBOSTON and LONDON, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a global gene therapy leader, expresses its strong appreciation for the passage of the Newborn Metabolic Screening Act in
3y agoORTXOrchard Therapeutics to Webcast Conference Call of Second Quarter 2023 Financial ResultsGlobeNewswireBOSTON and LONDON, July 25, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a global gene therapy leader, today announced that the company will host a conference call and live webcast on Thursday, August
3y agoORTXOrchard Therapeutics Announces Second Closing of Strategic Financing, Resulting in $34 Million of Additional CapitalGlobeNewswireFunding from second closing extends cash runway to mid-2025 to advance the company's HSC gene therapy portfolio through several potential value-creating milestones OTL-200 (MLD) BLA submission initiated and on track for
3y agoORTXOrchard Therapeutics to Present at Stifel's Genetic Medicines DayGlobeNewswireBOSTON and LONDON, May 24, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a global gene therapy leader, today announced that the company will make a virtual presentation at Stifel's Inaugural Genetic
3y agoORTXOrchard Therapeutics Announces Positive Clinical and Preclinical Data in Programs Targeting Neurometabolic and CNS Disorders at ASGCTGlobeNewswireNew OTL-203 proof-of-concept data demonstrate extensive metabolic correction in the skeletal system of patients with MPS-IH including normal growth rates, improvement in joint function and progressive acquisition of
3y agoORTXOrchard Therapeutics Presents Data from Research Programs at ASGCT Demonstrating the Ability of HSC Gene Therapy to Address Larger IndicationsGlobeNewswirePreclinical proof-of-concept data show the therapeutic potential of OTL-104 for NOD2 Crohn's disease, a severe and treatment-refractory form of the disease In vivo data demonstrate the development of CAR-Treg cells from
3y agoORTXOrchard Therapeutics Reports First Quarter 2023 Financial Results and Announces Initiation of Rolling Submission for Biologics License Application of OTL-200 for Metachromatic Leukodystrophy to U.S. FDAGlobeNewswireOTL-200 Biologics License Application (BLA) submission completion anticipated in mid-2023 Libmeldy revenue and commercial patients treated expected to grow year-over-year in 2023 New clinical data in MPS-I and
3y agoFULC ORTX PIRS VYGROMass Therapeutics Announces Appointment of New Board Chair and Series B ExtensionGlobeNewswirePRESS RELEASE OMass Therapeutics Announces Appointment of New Board Chairand Series B Extension Jim Geraghty joins as Independent Director and Chair, bringing US and international experience from Genzyme and as NED and
3y agoORTXOrchard Therapeutics Announces New Clinical and Pre-clinical Data at ASGCT 2023GlobeNewswireSix presentations showcase the differentiated profile and broad applicability of the company's HSC gene therapy platform Oral presentations in MPS-IH and MPS-IIIA and the progranulin form of frontotemporal dementia
3y agoORTXOrchard Therapeutics to Present at Guggenheim Genomic Medicines and Rare Disease DayGlobeNewswireBOSTON and LONDON, March 30, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a global gene therapy leader, today announced that the company will make a virtual presentation at the Guggenheim Genomic
3y agoORTXOrchard Therapeutics Completes ADS Ratio ChangeGlobeNewswireBOSTON and LONDON, March 10, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a global gene therapy leader, today announced that the Company's previously disclosed change to its American Depositary Share
3y agoORTXOrchard Therapeutics Provides Business Update and Reports 2022 Financial ResultsGlobeNewswireOTL-200 pre-BLA meeting granted for second quarter of 2023 following productive clinical Type B meeting with the U.S. Food and Drug Administration (FDA) Strategic financing from leading healthcare investors provides up
3y agoORTXOrchard Therapeutics Announces Strategic Financing Totalling up to $188 MillionGlobeNewswireProceeds to accelerate commercialization of Libmeldy and advance the company's HSC gene therapy R&D portfolio Initial closing of $34 million to support execution and extend cash runway into 2025 with potential for
3y agoORTXOrchard Therapeutics to Present at Multiple Investor Conferences in March 2023GlobeNewswireBOSTON and LONDON, March 03, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a global gene therapy leader, today announced that members of the management team will present at the following investor
3y agoORTXOrchard Therapeutics Announces Agreement Enabling Reimbursed Access to Libmeldy for All Eligible MLD Patients in SwedenGlobeNewswireBOSTON and LONDON, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a global gene therapy leader, today announced it has reached an agreement with the New Therapies (NT) Council which will result
3y agoORTXOrchard Therapeutics Announces Presentation of Updated Integrated Analysis of OTL-200 in MLD and Reports Progress with Newborn Screening Efforts at the 19th Annual WORLDSymposium™GlobeNewswireAdministration of one-time gene therapy resulted in statistically significant improvement in severe motor impairment-free survival with up to 11 years of follow-up (median 6.15 years) Composite primary endpoint used
3y agoORTXOrchard Therapeutics Announces Proposed ADS Ratio ChangeGlobeNewswireBOSTON and LONDON, Feb. 10, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a global gene therapy leader, today announced that it plans to change the ratio of its American Depositary Shares
3y agoORTXOrchard Therapeutics Announces Comprehensive Presence at 19th Annual WORLDSymposiumGlobeNewswireBOSTON and LONDON, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a global gene therapy leader, today announced a series of presentations from across its neurometabolic portfolio will be featured
3y agoORTXOrchard Therapeutics Highlights Recent Progress Across HSC Gene Therapy Portfolio and Outlines Key 2023 MilestonesGlobeNewswireLibmeldy® revenue totaled $5.8M in Q4 2022 and $18.8M for the full year with commercial expansion activities continuing in Europe Clinical Type B meeting with U.S. FDA to take place in early 2023 prior to OTL-200
3y agoORTXOrchard Therapeutics Announces U.S. FDA Clearance of IND Application for OTL-203 in MPS-IHGlobeNewswireBOSTON and LONDON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a global gene therapy leader, today announced the U.S. Food and Drug Administration (FDA) has cleared its Investigational New
3y agoORTXOrchard Therapeutics Announces Promising Early Neurocognitive Outcomes from Ongoing Proof-of-concept Study of OTL-201 in MPS-IIIAGlobeNewswireAll patients achieved sustained engraftment and supraphysiological SGSH enzyme levels with median 1.5 years follow-up Four out of five patients demonstrated gain of cognitive skills in line with development in healthy
3y agoORTXOrchard Therapeutics Announces Swissmedic Validation of the Marketing Authorization Application for Libmeldy (atidarsagene autotemcel)GlobeNewswireBOSTON and LONDON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a global gene therapy leader, today announced its marketing authorization application (MAA) for Libmeldy® (atidarsagene
3y agoORTXOrchard Therapeutics Reports Third Quarter 2022 Financial Results and Reviews Recent Business HighlightsGlobeNewswireLibmeldy® product sales totaled $4.8M in Q3 and $13.0M YTD with market expansion activities continuing in Europe First case of MLD confirmed from newborn screening study provides critical evidence to advance
4y agoORTXOrchard Therapeutics to Present at Multiple Investor Conferences in November 2022GlobeNewswireBOSTON and LONDON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a global gene therapy leader, today announced that members of the management team will present at the following investor
4y agoORTXOrchard Therapeutics to Webcast Conference Call of Third Quarter 2022 Financial ResultsGlobeNewswireBOSTON and LONDON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a global gene therapy leader, today announced that the company will host a conference call and live webcast on Monday, November
4y agoORTXOrchard Therapeutics Announces First Neurocognitive Data from OTL-201 Study in MPS-IIIA Accepted for Oral Presentation at ASH 2022GlobeNewswireBOSTON and LONDON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a global gene therapy leader, today announced early clinical findings from its ongoing proof-of-concept study of investigational
4y agoORTXOrchard Announces Multiple Presentations at 2022 ESGCT Annual Congress Showing the Potential of HSC Gene Therapy in Several Therapeutic AreasGlobeNewswireClinical and pre-clinical data from across the company's portfolio will be featured in four oral and six poster presentations Co-founder and Chief Executive Officer Bobby Gaspar to give invited talk exploring the
4y agoORTXOrchard Therapeutics Announces Multiple Presentations at 2022 SSIEM Annual Symposium Highlighting Neurometabolic Disease PortfolioGlobeNewswireBOSTON and LONDON, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a global gene therapy leader, today announced seven presentations from across its neurometabolic portfolio will be featured at the Society for the Study of Inborn
4y agoORTXOrchard Therapeutics Reports Second Quarter 2022 Financial Results and Reviews Recent Business HighlightsGlobeNewswireAdditional Libmeldy® reimbursement discussions advancing across Europe with product sales totaling $3.1M in Q2 and $8.2M YTD OTL-200 U.S. BLA filing for MLD on track for late 2022 / early 2023 Seven abstracts accepted at SSIEM highlight potential